In 2023, American cancer centers ran short of cisplatin, a decades-old generic chemotherapy drug.
About half of the US supply came from one plant in India. After FDA inspectors reported severe deficiencies there in late 2022, the company halted production. By late May 2023, 70% of 27 leading cancer centers surveyed lacked cisplatin, and 93% lacked carboplatin.
In 1983, Peter Kraljic gave buyers a way to see this coming. Sort every item by profit impact and supply risk. A low-value item with few sources is a bottleneck item, and Kraljic's advice was to secure volume, at a premium if necessary.
A decision rule for the next tender list:
- Flag every item with one or two qualified manufacturers, whatever its price.
- For flagged items, weigh delivery and quality evidence above the last saving on unit price.
- Agree on buffer stock or a second approved source before awarding.
The rule has a boundary. A Penn Medicine study later found no rise in death rates, as oncologists turned to alternatives that can cost far more. The bill moved elsewhere.
Unit price tells you what an item costs. Supply risk tells you what its absence costs.
